GlobeNewswire Inc. · Mar 14, 2022
GlucoTrack, Inc. Announces Effectiveness of Corporate Name Change and Ticker Symbol Change
To begin trading under the Nasdaq Symbol GCTK
IG
NASDAQ · IGAP
GlucoTrack, Inc.
Healthcare · Medical - Instruments & Supplies
$3.24
Up+$0.09 (+2.86%)
Updated Aug 25, 2026, 6:53 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 50.23M
- P/E ratio
- -0.66
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 501
- Avg. volume
- 5.95K
Price performance
IGAP price history
1M range · 0 trading sessions · Daily adjusted prices
IGAP does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest IGAP news
The latest Smart Investors Daily articles mentioning IGAP.
Stock researchCompany · Overview
IGAP research
Overview
Company profile and research snapshot.
Company profile
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Europe and the Asia Pacific. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
GlobeNewswire Inc. · Dec 21, 2021
Integrity Applications veröffentlicht einen Brief mit Neuigkeiten für Anteilseigner
Wilmington, DE und Or Yehuda, Israel, 20, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Integrity Applications, Inc. (www.integrity-app.com) (NASDAQ: IGAP), Erfinder von GlucoTrack®, einem nicht-invasivem Gerät zur Messung der Glukosewerte bei Personen mit Diabetes Typ II und Prädiabetes, hat heute angekündigt, dass Paul V. Goode, PhD, Präsident und Chief Executive Officer, eine Nachricht und einen Brief mit aktuellen Informationen für Anteilseigner veröffentlicht hat.
GlobeNewswire Inc. · Dec 21, 2021
Integrity Applications diffuse sa lettre d'information aux actionnaires
Wilmington, DE et Or Yehuda, Israël, 21 déc. 2021 (GLOBE NEWSWIRE) -- Integrity Applications, Inc. (www.integrity-app.com) (NASDAQ : IGAP), créateur du dispositif médical non invasif GlucoTrack® qui permet de mesurer les taux de glucose chez les personnes atteintes de diabète et pré-diabète de type II, a annoncé aujourd'hui la diffusion par Paul V. Goode, président-directeur général de la société, d'un message et d'un courrier d'actualités annuelles à destination des actionnaires.
GlobeNewswire Inc. · Dec 20, 2021
Integrity Applications Issues Shareholder Update Letter
Wilmington, DE and Or Yehuda, Israel, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Integrity Applications, Inc. (www.integrity-app.com) (NASDAQ: IGAP), innovator of GlucoTrack®, a non-invasive device for measuring glucose levels in people with Type II diabetes and prediabetes announced today that Paul V. Goode, PhD, President and Chief Executive Officer has provided a message and year-to-date shareholder update letter.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
